NKX3-1 and bladder transitional cell carcinoma: Combination of NKX3.1, PSA, uroplakin II and S100P is therefore proposed to be the favored immunohistochemical test to resolve the dilemma of distinguishing between bladder urothelial carcinomas and prostate adenocarcinoma.